Health ❯ Healthcare ❯ Clinical Trials ❯ Phase 3 Trials

C-POST Trial

EU Regulators Back Libtayo as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

The move reflects phase 3 C-POST evidence showing a substantial disease-free survival benefit in resected high-risk CSCC.

FDA Approves Libtayo as First Immunotherapy for Adjuvant Treatment of High‑Risk CSCC